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Abstract
Background: Although the effects of probiotics on the immune system have been extensively evaluated
under disease states, their role in healthy situations remains unclear, since changes are hardly expected under
immunological homeostasis. EFSA indicates that vaccination protocols could be used to evaluate the potential
role of probiotics to improve the immune response against antigen challenges. The aim of the study was to
evaluate the effect of Lactobacillus coryniformis CECT5711 (Lc) on the specific immunity of healthy volunteers
undergoing vaccination with Hepatitis A virus (HAV).
Methods: One hundred twenty-three healthy adults were randomised into three groups to follow a 6-week (wk)
intervention and all received an intramuscular HAV vaccine 2 weeks after starting the intervention: 1) PRO1 received
Lc for 2weeks (1 capsule/day; 3 × 109 CFU/capsule) and placebo capsules after vaccination; 2) PRO2 received a daily
capsule of Lc (3 × 109 cfu/day) before and after the challenge; 3) Control group (C) received a daily placebo capsule
before and after the vaccine. Blood samples were collected at the beginning (visit 1; V1) and after 2 (V2) and 6 weeks
(V3) of the intervention. At each visit, lymphocyte subset counts and cytokine levels were analysed. Specific HAV
antibodies were analysed at V1 and V3. To evaluate differences between groups, one-way ANOVA with Bonferroni
post-hoc test were used regarding lymphocyte subset counts and specific HAV antibodies production, and Friedman
test of related samples and Kendall concordance coefficient for cytokines production. Chi square test was used to
analyse seroconversion rates.
Results: Specific HAV antibodies were significantly higher in PRO1 (50.54 ± 29.57) compared to C (36.23 ± 16.
45) (P = 0.017) and showed an intermediate value in PRO2 (41.61 ± 15.74). Seroconversion rates were similar
in the three groups (97.3, 92.3 and 97.4% in C, PRO1 and PRO2 respectively). Memory T-helper lymphocytes
increased in V3 vs. V1 (P = 0.032) in PRO2. No differences were found in cytokine concentrations.
Conclusion: Mixed results have been found regarding the usefulness of Lc supplementation to increase the
antigen-specific antibody response to an immune challenge. Clinical trial registration number: EudraCT
Number 2016-000183-42. Registered 19 January 2016. Retrospectively registered.
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Background
There is wide evidence about how nutrition affects the
immune system and modulates the resistance to infec-
tion [1, 2]. Currently, there is a vast research about the
role of specific food components in enhancing immune
responses against a challenge with the aim to improve
health and reduce disease risks [3]. In this line, the inter-
est in probiotics has substantially increased over the last
two decades, which are well-defined as ‘live bacteria that
offer a health benefit to the host when administered in
adequate amounts’ [4]. Probiotics have been shown to
exert beneficial effects in health and disease in many stud-
ies [5, 6]. In particular, probiotic intake is related to a bet-
ter control of infectious diseases [7], and in some cases
with an improvement of the duration or severity of infec-
tions [8, 9]. The mechanism could be related to an inter-
action between probiotics and intestinal bacteria and thus
to the innate and specific host immune cells [10].
The European Food Safety Agency (EFSA) states that
vaccination protocols may be allowable in order to evalu-
ate the potential role of probiotic strains on improving the
immune response against antigen challenges [11]. In this
regard, the stimulation of protective antibody titres could
be used under standardized conditions to substantiate a
health claim on the function of the immune system re-
lated to defence against pathogens [11–13]. In fact, these
protocols have been already used in studies with healthy
subjects [14, 15]. Lactobacilli are considered potential
candidates to develop antigen delivery strategies for
immunization [4]; indeed, these bacteria have been in-
cluded in our diet into many fermented products for
centuries. In fact, the main objective of employing lactic
acid bacteria as coadjuvants in a vaccination process is to
gain a more efficient immune response [9].
The strain used in this study, L. coryniformis CECT5711,
was isolated from an artisan goat milk cheese [16] and it
has been recognised as QPS (qualified presumption of
safety) by EFSA. This strain has been proven to comply
with the main safety criteria [17] and the most important
properties for probiotics to exert their effects on the im-
mune system [16, 18]. In addition, it has been related to an
improvement of both innate and specific immune response
in previous studies in healthy subjects when consumed
along with L.gasseri CECT5714 [19, 20]. Since vaccine-
antibody response is mediated by the activation of both
responses, the aim of this study was to find out whether the
consumption of this single strain, under a Hepatitis A
vaccine model, could induce a vaccine-antibody response
and thus be used as a coadjuvant in a vaccination process.
Methods
Experimental design
This study is a randomized, double-blinded, placebo-
controlled, human intervention trial, which started on
May 2012 and finished on April 2013. A 2-weeks run-in
was performed prior to the intervention and followed
during all the study. During this time subjects were
asked to avoid any fermented food, probiotics or pre-
biotics consumption. All volunteers were vaccinated
at week 2 of the study in the medical service of the
“Spanish National Research Council (CSIC)”, with a
“HAVRIX 1440” inactivated Hepatitis A vaccine. The
intervention lasted 6 weeks (wk), which was divided into a
pre-vaccination period (2weeks before the intramuscular
vaccine), plus a post-vaccination period (4weeks following
the vaccine). Although the between-subject variability in
response to vaccination is normally quite high, the period
between vaccination and the plateau phase of the response
starts from about 3 weeks [12]. For this reason, the meas-
urement of antibody production was established after
4 weeks of vaccination. After an overnight fast, blood
samples were collected at the start of the intervention or
visit 1 (V1), after 2 weeks or visit 2 (V2) and after 6 weeks
or visit 3 (V3).
Subjects
Sample size calculation was performed to demonstrate a
5% difference in specific Hepatitis A antibody titers with
a power of 80% and a significance level of 0.05. Under
these assumptions, based in previous published work
[21], a sample size of at least thirty-six subjects per
group would be required. In total, 138 healthy adults
started the study, but only 123 finished the trial (Fig. 1).
The main dropout reasons were antibiotic treatment or
personal issues. The recruitment of the volunteers was
carried out through advertisement and on-line services.
The exclusion criteria were frequent gastrointestinal,
metabolic and immunological disorders (lactose intoler-
ance or food allergies), antibiotic treatment during two
months prior to the intervention or pregnancy. All vol-
unteers were young adults (aged 20–45 years), showing
a normal body mass index (BMI) (between 18.5 and
24.9 kg/m2) [22], who reported not to have been vacci-
nated or had suffered from Hepatitis A.
Volunteers included in the study were randomly allo-
cated into one of the three groups established: 1) PRO1
received a daily capsule of Lc for 2weeks (3 × 109 colony
forming units ([cfu]/capsule) and after vaccination
received placebo capsules with maltodextrin; 2) PRO2
received a daily capsule of Lc (3 × 109 cfu/day) before
and after the vaccine; 3) Control group (C) received a
daily placebo capsule with maltodextrin before and after
the vaccine. A stratified randomization procedure was
followed using a random number generator with an
informatics program and sex, age and BMI as potential
covariates. The capsules were kept in the fridge and
ingested after dinner. Baseline characteristics of the
volunteers are described in Table 1.
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Endpoints
Primary efficacy variable was vaccine-specific antibody
titers, including specifically IgG and IgM antibodies.
Secondary variables were seroconversion rate, serum
immunoglobulins (Ig A, IgE, IgG and IgM), lymphocytes
subsets (total T, naïve and memory T helper and naïve
and memory T cytotoxic lymphocytes, B lymphocytes,
Natural Killer (NK) cells) and cytokines production
(interleukin (IL)-4, IL-6, IL-13, IL-10, IL-12, interferon
(IFN)-γ and tumour necrosis factor (TNF)-α).
Blood analysis
Specific immunity
White blood cell (WBC) counts and differential were
determined with automated blood cell counters (ADVIA-
2120, Siemens, Madrid). Major lymphocyte subset pheno-
types were assessed in ethylenediaminetetraacetic acid
(EDTA)-treated whole blood samples. For this purpose,
blood aliquots were incubated for 30 min at room
temperature in the dark with fluorochrome-conjugated
monoclonal antibodies with a quadruple immunostaining
procedure (CD3/CD8/CD45/CD4, CD45RA/CD45RO/
CD8/CD3, CD45RA/CD45RO/CD4/CD3 and CD3/CD16
+ 56/CD45/CD19) in order to identify and quantify the
following lymphocyte subsets: total T lymphocytes (CD3
+), cytotoxic T lymphocytes (CD3 + CD8+), helper T lym-
phocytes (CD3 + CD4+), B lymphocytes (CD19+), Natural
Killer (NK) cells (CD3-CD16 + CD56+), naïve cytotoxic T
lymphocytes (CD8 + CD45RA+), memory cytotoxic T
lymphocytes (CD3 +CD8 + CD45RO+), naïve helper T
lymphocytes (CD4 + CD45RA+), and memory helper T
lymphocytes (CD3 + CD4 + CD45RO+) (BD Biosciences,
San José, CA, USA). After lysing red blood cells, lym-
phocytes were analyzed by flow cytometry on a FACS-
calibur system (BD Biosciences, San José, CA, USA).
The lympho-gate was defined on the forward and side
scatter patterns of lymphocytes. The analysis protocol
gated on lymphocytes stained with PerCP (Peridinin
chlorophyll) and/or APC (Allophycocyanin) and the
selected population was then analysed with the two
remaining colours FITC (Fluorescein isothiocyanate) and
PE (Phycoerythrin) to obtain percentages of cell express-
ing the specific antigens. For memory and naïve subsets,
the anchor marker used was annotated in the first place.
The results were expressed as the percentage and cell
number of mononuclear cells positively stained.
Fig. 1 Flowchart of participating subjects
Table 1 Baseline characteristics of the volunteers in each group in the immune general assessment (A) and in the Hepatitis A-














Men 13 13 12 11 13 10
Women 27 25 29 27 29 27
Age (mean ± SD, years) 26.7 ± 5.8 26.2 ± 5.2 27.1 ± 6.0 26.8 ± 5.8 25.8 ± 3.6 25.7 ± 3.8
Body Mass Index (mean ± SD, kg/m2) 22.1 ± 1.9 22.1 ± 1.9 22.4 ± 1.7 22.4 ± 1.7 21.9 ± 1.9 21.7 ± 1.8
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Serum immunoglobulins (Ig) A, IgE, IgG and IgM
levels were measured in EDTA-treated whole blood sam-
ples by immunoturbidometry.
Specific HAV antibodies were assessed with a competi-
tive Enzyme-Linked ImmunoSorbent Assay (ELISA) kit
(DIA.PRO, Italy), both before (V1) and after (V3) the
intervention [23]. A cut-off value (negative control + posi-
tive control/3) was used to confirm negative or positive
Hepatitis A results. The kit detects total anti-HAV IgM
and IgG levels (mUI/ml). Seroconversion was defined as
the proportion of subjects that change from a negative to
a positive result after vaccination, after exclusion of those
with positive results before the challenge.
Cytokine analysis
Blood was collected in Vacutainer tubes (BD Biosciences)
and allowed to clot. Within an hour, plasma was separated
by centrifugation at 3500 rpm for 15 min and aliquots
were stored at −80 °C. At the end of the study, multiplex
magnetic bead array (Merck-Millipore) was performed for
the quantification of immune and inflammation-related
cytokines: interleukin (IL)-4, IL-6, IL-13, IL-10, IL-12,
interferon (IFN)-γ and tumour necrosis factor (TNF)-α. In
the case of IL-4 and IL-13, there were 18.03 and 62.5% of
undetectable data respectively, which were not included
into the statistical analysis.
Statistical analysis
Kolmogorow-Smirnov test was performed to evaluate
the normality of the variables. For the variables fitting
Gaussian distribution, data were expressed as mean and
Standard Deviation (SD), and for the non-Gaussian vari-
ables data were expressed as median and Interquartil
Range (IQR, percentile 25, percentile 75). Logarithmic
transformation was used for the following variables not
fitting a normal distribution: CD19+ and CD16 + CD56+
lymphocyte subset percentages and CD19+, CD8 +
CD45RA+, CD4 + CD45RA+, CD3 + CD8 + CD45RO+,
CD3 + CD4 + CD45RO+, and CD16 + CD56+ counts.
One-way ANOVA with Bonferroni post-hoc test were
performed for normally-distributed variables to evaluate
the “group effect” within each visit, and a lineal mixed
model of repeated measures was performed to analyse
the “visit effect” in the different groups (fixed factor
“visit” and random factor “sex”). For those variables not
fitting normal distribution (all cytokine variables and IgE
levels), non-parametric Kruskal-Wallis test and Mann-
Whitney U test were performed for group comparisons
within visits and Friedman’s test for paired samples was
used for between visit comparisons within the same
group. The Chi square test was used to assess sero-
conversion rates. Data analysis was performed using
SPSS v.19 Software. P values <0.05 were considered
significant.
Results
Regarding white blood cells counts and differential, no
differences were found between groups in each visit, nor
within each group along the intervention (Additional file 1:
Table S1).
Effects on specific immunity
Inter-group comparisons showed no significant effect of
treatment on lymphocyte subset percentages (Additional
file 1: Table S2), but a significant increase in memory T
helper lymphocyte counts (CD3 + CD4 + CD45RO+) was
found in PRO2 at the end of the intervention (V3) com-
pared to basal values (V1) (P = 0.032) (Table 2).
Although there were no changes regarding plasma im-
munoglobulin levels (Additional file 1: Table S3), PRO1
showed significantly higher values of specific HAV anti-
bodies compared to the control group after 6 weeks of
intervention (P = 0.017) (Table 3). PRO1 HAV-antibody
levels were 39% higher compared to the control group
titres, while those of PRO2 were only 14.8% higher.
Seven volunteers (5.7%) showed positive HAV Ab levels
at V1, probably due to an ignored previous contact with
the virus, and were thus excluded from the analysis. In
addition, there were 5 volunteers with negative titers
against HAV specific antibodies after four weeks of vac-
cination (4.3%); more days might be necessary for these
volunteers to produce enough antibodies for a positive
response. Therefore, seroconversion rates were 97.3,
92.3 and 97.4% in C, PRO1 and PRO2 respectively,
values that were not significantly different.
Effects on cytokine levels
No significant differences were found among the differ-
ent groups at any visit. In addition, serum cytokine levels
did not change along the study in the treated groups.
However, C group showed an increase in TNF-α values
from V1 to V2 (P = 0.052) and reaching statistical signifi-
cance after 6 weeks of intervention (P = 0.011 V1 vs.
V3). Similarly, IL-10 values showed a marginal increase
from V1 to V2 (P = 0.058), reaching statistical signifi-
cance compared with V3 (P = 0.016; V1 vs. V3). How-
ever, IFN-γ values decreased during the first two weeks
of the intervention V1 to V2 (P = 0.037) in this group
(Table 4).
Discussion
Specific strains of probiotics interact with host cells and
intestinal microbiota, and could thus have a role as im-
mune modulators not only in patients with disease but
also in healthy subjects under specific circumstances,
such as an immune challenge as performed in this study.
In fact, our findings showed that the consumption of Lc
during two weeks before vaccination seems to be associ-
ated with an enhanced antibody response. However, the
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regular intake of this strain prior and following the chal-
lenge did not increase antibody titres but led to an
increase in memory T helper lymphocytes.
L. coryniformis CECT5711 intake did not change the
percentage and number of total T lymphocytes, includ-
ing helper and cytotoxic T cells, B lymphocytes and NK
cells. On the contrary, L. coryniformis CECT5711 in
combination with L. gasseri CECT5714 consumed in a
dose of 106 cfu/g each during three months, led to an
enhancement of NK cells in allergic children [24]. The
effect of this combination on NK cells was also observed
in healthy subjects after two weeks of treatment [25]. In
agreement with the lack of effect on lymphocyte subsets
in our results, several studies with different Lactobacillus
strains supplementation in healthy individuals have also
shown no significant effects on CD3+, CD4+, CD8+ and
CD19+ percentages [25, 26]. Therefore, probiotics may
affect the activity of certain immune cell types and not
others, being the differences due to probiotic strain
specificity.
There was an increase in memory T helper lympho-
cytes (CD3 + CD4 + CD45RO+) after the vaccine chal-
lenge in the group that consumed the probiotic strain
during 6 weeks (PRO2), which might be linked to the
establishment of immunological memory against the
viral antigen. However, further research should be aimed
to confirm the production of HAV specific memory CD4
+ T cell clones, since specific memory cells can be reac-
tivated after a secondary microbial exposure and are
related to a long term protection [27]. The effect on
lymphocyte subsets of a vaccination protocol against in-
fluenza virus while consuming L. fermentum CECT5716
(1010 cfu/d) was found to increase the percentage of
helper and cytotoxic T cells after a two week challenge
both in the placebo and treated groups [15]. The differ-
ent timing in lymphocyte subset analysis between studies
might explain why we did not observe the same increase
in T cells, since we measured it after four weeks of vac-
cination. In addition, the nature of the vaccine antigen
(bacterial or protein/ live or non live vaccines) and its
administration could be main determinants in the im-
mune response elicited after a vaccine shot [8] and thus
relevant to evaluate differences between studies.
The specific production of antibodies in response to
vaccination is considered as a useful measure which
directly correlates with specific protection and the ‘gold-
standard’ to determine the influence of probiotics on
immunity [28]. In this regard, studies in animals and
Table 2 Lymphocytes subsets (cells/μL) at the beginning (V1),
after 2 (V2) and 6 weeks (V3) of intervention
V1 V2 V3
Mean SD Mean SD Mean SD P#
CD3+ Lymphocytes
Control 1851 589 1817 626 1865 507 NS
PRO2 1660 522 1695 496 1861 558 NS
PRO1 1812 494 1802 422 1876 401 NS
CD8+ Lymphocytes
Control 611 229 608 250 605 191 NS
PRO2 512 217 519 236 576 239 NS
PRO1 543 193 536 194 553 171 NS
CD4+ Lymphocytes
Control 1073 382 1034 420 1104 387 NS
PRO2 992 345 1007 315 1132 395 NS
PRO1 1111 323 1099 280 1160 278 NS
CD19+ Lymphocytes
Control 248 102 248 98 250 123 NS
PRO2 234 101 251 89 261 105 NS
PRO1 273 104 289 120 285 114 NS
CD3-CD16 + CD56+ Cells
Control 299 154 272 164 278 169 NS
PRO2 275 138 281 144 236 105 NS
PRO1 328 196 311 172 305 165 NS
CD8 + CD45RA+ Lymphocytes
Control 336 158 326 170 337 138 NS
PRO2 282 158 290 137 327 159 NS
PRO1 304 136 290 132 309 309 NS
CD3 + CD8 + CD45RO+ Lymphocytes
Control 291 147 269 113 274 109 NS
PRO2 232 108 235 126 211 133 NS
PRO1 263 110 251 115 256 104 NS
CD4 + CD45RA+ Lymphocytes
Control 443 245 413 242 451 246 NS
PRO2 405 218 405 204 454 247 NS
PRO1 483 224 452 174 513 205 NS
CD3 + CD4 + CD45RO+ Lymphocytes
Control 581 195 562 193 630 217 NS
PRO2 551a 213 594ab 215 660b 223 0.032
PRO1 565 221 583 196 616 200 NS
Data are expressed as mean ± SD. #Differences among visits within each
group, also highlighted in bold. Repeated measures ANOVA with “visit” as
fixed factor and “sex” as randomized factor (P < 0.05). Different superscripts
mean significant differences between visits; Bonferroni test (P < 0.05)
Table 3 Specific HAV antibodies (mIU/mL) at the beginning
(V1) and after 6 weeks (V3) of intervention
Control (n = 38) PRO2 (n = 38) PRO1 (n = 37) P#
V1 Neg Neg Neg –
V3 36.23 ± 16.45a 41.61 ± 15.74ab 50.54 ± 29.57b 0.017
Data are expressed as mean ± SD. #Differences among groups by one-way
ANOVA (P < 0.05), also highlighted in bold. Different superscripts mean signifi-
cant differences between visits; Bonferroni test (P < 0.05)
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humans have shown the potential of probiotics to act as
immune adjuvants [9], with an effect on specific vaccine
antibody production in susceptible population groups
such as children [29–32] and elderly people [33, 34].
The current study is the first to use a vaccine chal-
lenge to assess the immune modulation exerted by the
L. coryniformis CECT5711 strain in healthy adults. The
effect of probiotics as vaccine adjuvants has previously
been shown with other strains. The oral administration
of the L. fermentum CECT5716 strain has been found to
enhance the immune response of an anti-influenza
vaccine and provide systemic protection from infection
by increasing antigen specific IgA, but not IgG levels in
50 subjects [15]. In addition, the intake of B. animalis
ssp. lactis and L. paracasei ssp. paracasei for 6 weeks
have been shown to increase influenza vaccine-specific
serum IgG measured 4 weeks after vaccination com-
pared to placebo in 211 adults [10]. However, no effects
in influenza A–specific IgG1 and IgG3 seroconversion
measured three weeks after the vaccine were observed
after the consumption of L. paracasei subsp. Paracasei
431 in 1066 healthy subjects. Protection rate after a
seasonal influenza vaccine varies from year to year and
these studies were performed in different campaigns, so
the differences in the viral challenges between cam-
paigns could also contribute to the different results
found among these studies. Since rates up to 99%
seroprotection were observed in Jespersen’s et al. study,
the authors hypothesized that it might be difficult to ob-
serve a further increase in protection rates due to the
Table 4 Cytokines (pg/mL) at the beginning (V1), after 2 (V2) and 6 weeks (V3) of intervention
V1 V2 V3
Median IQR Median IQR Median IQR P#
TNF-α
Control 3.43a 2.56–4.97 3.83 ab 2.98–4.76 4.03b 2.80–4.98 0.019
PRO2 4.20 3.38–5.41 4.63 3.66–5.79 4.07 3.22–6.28 NS
PRO1 4.23 3.77–5.43 4.35 3.34–5.79 4.60 3.08–6.28 NS
IFN-γ
Control 6.26a 2.96–10.75 6.11b 3.24–12.02 5.97ab 3.31–12.75 0.049
PRO2 9.47 2.91–17.46 9.28 4.68–15.94 8.51 5.05–13.77 NS
PRO1 7.55 3.73–16.36 7.75 4.10–21.40 9.15 4.95–15.72 NS
IL-4
Control 6.65 3.03–25.23 9.04 2.04–24.57 9.12 2.34–22.38 NS
PRO2 2.95 0.21–14.60 4.93 0.61–22.78 3.75 1.46–22.42 NS
PRO1 6.96 1.08–21.74 6.11 1.29–29.09 10.22 2.16–15.38 NS
IL-13
Control 3.47 0.39–8.46 2.57 0.52–9.57 2.73 1.28–6.18 NS
PRO2 2.73 0.19–5.44 2.50 0.70–8.77 3.24 0.33–8.55 NS
PRO1 2.79 0.93–8.50 2.33 0.96–7.21 1.22 0.10–4.73 NS
IL12p70
Control 3.66 1.22–5.07 4.35 1.85–7.04 4.41 2.41–7.91 NS
PRO2 5.09 1.40–10.07 5.33 2.72–8.17 4.46 3.03–9.37 NS
PRO1 5.00 2.67–9.88 4.96 2.17–13.51 5.41 2.79–12.86 NS
IL-10
Control 21.85a 11.87–32.52 24.77ab 16.26–35.42 25.23b 16.74–42.47 0.030
PRO2 27.07 13.44–44.61 29.29 19.16–53.47 30.37 19.37–40.75 NS
PRO1 31.53 20.13–48.29 33.90 16.39–49.96 34.23 16.97–57.00 NS
IL-6
Control 1.10 0.46–1.81 1.15 0.57–2.70 1.17 0.56–2.10 NS
PRO2 2.11 0.76–3.30 2.66 0.63–3.72 1.87 0.68–3.86 NS
PRO1 1.70 0.79–3.46 1.31 0.79–3.46 1.82 0.97–2.97 NS
Data are expressed as median and interquartile range (IQR. percentile 25-percentil 75). # Differences among visits within each group by Friedman’s test for related
samples, also highlighted in bold. Different superscripts mean significant differences between visits (Friedman’s test; P < 0.05)
Redondo et al. Nutrition & Metabolism  (2017) 14:2 Page 6 of 9
probiotic intake [35]. In the current study, the con-
sumption of the probiotic strain during 2 weeks in
PRO1 induced an increase in Hepatitis A-specific anti-
bodies after the vaccine, compared to the control group
(P = 0.017). The immunological mechanism elicited
after a vaccine challenge involves the activation of im-
mature dendritic cells (DCs) by local inflammation,
which take up the vaccine antigens and migrate to
draining lymph nodes where the activation of T and B
lymphocytes will take place. T cell help induces B cell dif-
ferentiation into Ig secreting plasma cells that produce
low-affinity IgG antibodies during this primary antibody
response. Therefore, L. coryniformis CECT5711 might act
as a coadjuvant of the antibody response in a vaccination
protocol in healthy subjects when consumed before the
vaccine challenge. This improvement in vaccine response
could be relevant, since there is a low percentage of
supposedly healthy individuals who exhibit an impaired
response to the immune challenge of this vaccine and
sometimes it needs an extra booster. In addition, EFSA
states that “the stimulation of protective antibody titters in
response to vaccination could be used to substantiate a
health claim on the function of the immune system re-
lated to defence against pathogens” [11].
The fact that the increase of specific antibodies was
not significant in PRO2 compared to placebo is difficult
to explain. It might suggest that the probiotic consump-
tion two weeks before vaccination works better as adju-
vant of the humoral response than the continuation of
L. coryniformis administration after vaccination; how-
ever, the level of specific HAV antibodies in PRO2 was
at an intermediate level between the other two groups.
In this sense, the continuous intake of this strain during
6 weeks in PRO2 could induce a higher T cell expansion,
which is the main determinant of memory T cell
responses and a weaker antibody response compared to
the response induced when the strain was consumed
only during 2 weeks in PRO1. In addition, regulatory
T cell responses should be further evaluated in another
study since an inverse relationship was observed between
Tregs and antibody responses [36]. In fact, an enhance-
ment of anti-cancer vaccine responses was observed in
healthy adults following Tregs depletion [37]. No effects
in inflammatory cytokines were seen when consuming the
probiotic strain, in contrast to the placebo group, which
showed higher levels of the pro-inflammatory TNF-α
cytokine and the anti-inflammatory IL-10 four weeks after
the vaccine, probably as an on-going reaction to the chal-
lenge [38]. In this context, the probiotic intake might have
modulated the cytokine response to the vaccine. Although
the early cytokine response after the shot was not evalu-
ated, we could speculate that the probiotic intake might
favour an early recovery of immunological homeostasis.
On this basis, since mixed results were found depending
on the timing and length of supplementation with the
probiotic in relation to the viral challenge, we consider
that one limitation of this study was the lack of certain
additional times and immune measurements, such as in-
nate immunity 2 weeks after vaccination and regulatory T
cells at 4 weeks post-vaccination, in order to ascertain the
role of the lactobacillus strain as an adjuvant for HAV
vaccine.
Conclusions
L. coryniformis CECT5711 strain consumed two weeks
before the vaccine led to an increase of total HAV anti-
body titres compared to placebo. This supports the
hypothesis that the consumption of this strain might
have a clinical benefit in protection from future infections.
However, an independent study is warranted to clarify the
adjuvant effects obtained with specific protocols of Lc
supplementation and the mechanisms involved.
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S3 Immunoglobulin levels in plasma samples expressed as mean ± SD at
the beginning (V1), after 2 weeks (V2) and after 6 weeks (V3) of the
intervention in all groups. Description of data: Data from analyses which
did not show statistical significance. (DOCX 36 kb)
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coryniformis; NK: Natural killer; PBMCs: Peripheral blood mononuclear cells;
PE: Phycoerythrin; PerCP: Peridinin chlorophyll; QPS: Qualified Presumption of
Safety; RPMI: Roswell Park Memorial Institute; SD: Standard desviation;
TGF: Transforming growth factor; TNF: Tumour necrosis factor; V: Visit;
WBC: White blood cells; WHO: World Health Organization; wk: Week
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